11ß-HSD1 and Metabolic Syndrome

• Status: Completed
• Trial end date: 2008-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether the insulin sensitizing effects of rosiglitazone were accompanied by changes in 11ß-HSD1 expression and activity in different tissues. Furthermore the metabolic and hormonal effects of PPAR gamma stimulation by rosiglitazone will be analysed in several tissues.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Charite University, Berlin, Germany
• Treatments: Rosiglitazone

Criteria

Inclusion Criteria:

• Impaired glucose tolerance

Exclusion Criteria:

• Treatment with insulin

• Orally taken antidiabetic medication, glucocorticoids or vitamin K-antagonists

• Heart failure

• Impaired hepatic or renal function

• Anaemia

• Disturbed coagulation

• Any other endocrine disorder